摘要
目的:探讨三氧化二砷联合维甲酸(ATRA)治疗MDS的疗效。方法:31例MDS患者均采用三氧化二砷联合维甲酸等治疗。结果:RA+RAS组有效率87.1 %,RAEB+RAEB蛳T组有效率42.9 %。结论:三氧化二砷是一种治疗MDS的有效药物,尤其是在RA的治疗中有显著效果。
Objective: To observe the efficacy of arsenic trioxide cssocidted with ATRA in the treatment of MDS. Methods: 31 cases MDS patients were enrolled in this trial. The arsenic trioxide associated with ATRA was admitted to these MDS patients. Results: 20 of 21 cases of the MDS RA patients showed the improvement and the rate of the improvement is 87.1 %. Conclusion: Arsenic trioxide is a new and effective drug in the treatment of MDS, especially in the RA subgroup.
出处
《白血病.淋巴瘤》
CAS
2004年第2期96-97,共2页
Journal of Leukemia & Lymphoma